Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: Case report

Medicine (United States)

Volumn 93, Issue 28, 2014, Pages e161-

  Orouji, Elias ^a   Ziegler, Birgit ^a   Umansky, Viktor ^a   Gebhardt, Christoffer ^a   Utikal, Jochen ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; SULFONAMIDE;

ADULT; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DRUG RESPONSE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTE COUNT; METASTATIC MELANOMA; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; NEUTROPENIA; NEUTROPHIL COUNT; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; MELANOMA; SECONDARY; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMIDAZOLES; INDOLES; LEUKOCYTE COUNT; LEUKOPENIA; MELANOMA; MIDDLE AGED; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84920161675     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000161     Document Type: Article

References (6)

1. Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013; 31: 3205-3211.
2. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367: 1694-1703.
3. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014; 15: 323-332.
4. Schilling B, Sondermann W, Zhao F, et al. Differential influence of vemurafenib and dabrafenib on patients? lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol. 2014; 25: 747-753.
5. Hong DS, Vence L, Falchook G, et al. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res. 2012; 18: 2326-2335.
6. Bouwhuis MG, ten Hagen TL, Eggermont AM. Immunologic functions as prognostic indicators in melanoma. Mol Oncol. 2011; 5: 183-189.